News

Remembering Dr. Paul I. Terasaki

Remembering Dr. Paul I. Terasaki

Pioneer transplantation scientists who discovered the link between ankylosing spondylitis and HLA-B27 in the US.

Dr. Paul I. Terasaki, Professor Emeritus of Surgery at the UCLA Geffen School of Medicine, passed away on January 25th, 2016 at the age of 86. Besides being one of the most important transplantation scientists, and establishing the largest transplantation registry of his time, Dr. Terasaki was responsible for discovering the linkage between HLA-B27 and ankylosing spondylitis in the U.S. in 1971.
Monday, February 01, 2016/Author: Elin Aslanyan/Number of views (477)/Comments ()/
Categories: Weekly News
Tags:
The Worldwide Prevalence of Spondyloarthritis

The Worldwide Prevalence of Spondyloarthritis

Just how common is spondyloarthritis globally? Is it more common in certain parts of the world and populations than others? And are we close to being able to estimate the number of people worldwide who have spondyloarthritis?
Monday, January 25, 2016/Author: Elin Aslanyan/Number of views (1476)/Comments ()/
Categories: Weekly News
Tags:
Upcoming Free Webinar - “Troubleshooting Spondylitis: Managing Complications”

Upcoming Free Webinar - “Troubleshooting Spondylitis: Managing Complications”

Presented by Rheumatologist, Lianne Gensler, MD.

Join us on Saturday, February 6th, at 11:00 AM Pacific Time to learn about possible complications and comorbidities associated with spondyloarthritis.
Monday, January 25, 2016/Author: Spondylitis Association of America/Number of views (2658)/Comments ()/
Categories: Weekly News
Tags:
Seeing the Invisible: Musculoskeletal Imaging and Spondyloarthritis

Seeing the Invisible: Musculoskeletal Imaging and Spondyloarthritis

Watch Now

The recording of our recent, cutting edge MRI webinar is now available!
Wednesday, January 20, 2016/Author: Spondylitis Association of America/Number of views (1465)/Comments ()/
Categories: Weekly News
Tags:
ARTICLE UPDATED (JANUARY 19, 2016): NEW MEDICATION APPROVED - A brand new kind of biologic medication for ankylosing spondylitis and psoriatic arthritis

ARTICLE UPDATED (JANUARY 19, 2016): NEW MEDICATION APPROVED - A brand new kind of biologic medication for ankylosing spondylitis and psoriatic arthritis

Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis

Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved for adult patients with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA)
Tuesday, January 12, 2016/Author: Elin Aslanyan/Number of views (12130)/Comments ()/
Categories: Weekly News
Tags:
RSS
12345678910Last